Overview

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

Status:
Unknown status

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

Clinical Phase I/II study to investigate the feasibility and tolerability of synthetic adjuvant peptide immunisation in combination with immune adjuvants (granulocyte macrophage colony stimulating factor; Montanide ISA-51) in patients with advanced renal cell cancer (RCC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University Hospital Tuebingen

Treatments:

Freund's Adjuvant
Molgramostim
Sargramostim
Vaccines